CompletedPhase 3NCT00000802
A Randomized, Comparative Study of Daily Dapsone and Daily Atovaquone for Prophylaxis Against PCP in HIV-Infected Patients Who Are Intolerant of Trimethoprim and/or Sulfonamides
Studying Pneumocystosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Principal Investigator
- El-Sadr W
- Intervention
- Atovaquone(drug)
- Enrollment
- 700 target
- Eligibility
- 13 years · All sexes
- Timeline
- 1997
Study locations (30)
- Alabama Therapeutics CRS, Birmingham, Alabama, United States
- USC CRS, Los Angeles, California, United States
- Stanford CRS, Palo Alto, California, United States
- Ucsd, Avrc Crs, San Diego, California, United States
- Ucsf Aids Crs, San Francisco, California, United States
- Santa Clara Valley Med. Ctr., San Jose, California, United States
- San Mateo County AIDS Program, San Mateo, California, United States
- Harbor-UCLA Med. Ctr. CRS, Torrance, California, United States
- University of Colorado Hospital CRS, Aurora, Colorado, United States
- Howard University Hosp., Div. of Infectious Diseases, ACTU, Washington D.C., District of Columbia, United States
- Univ. of Miami AIDS CRS, Miami, Florida, United States
- Emory Univ. Hemophilia Program Office, Atlanta, Georgia, United States
- Queens Med. Ctr., Honolulu, Hawaii, United States
- Univ. of Hawaii at Manoa, Leahi Hosp., Honolulu, Hawaii, United States
- Northwestern University CRS, Chicago, Illinois, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00000802 on ClinicalTrials.govOther trials for Pneumocystosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT04851015Low Dose Trimethoprim-Sulfamethoxazole for the Treatment of Pneumocystis Jirovecii PneumoniaTodd C. Lee MD MPH FIDSA
- RECRUITINGPHASE4NCT06499233Efficacy and Safety of Prophylactic Treatment for Pneumocystis Jirovecii Pneumonia in Patients With Autoimmune Inflammatory Rheumatic DiseaseTongji Hospital
- ACTIVE NOT RECRUITINGNCT06431958Droplet Digital PCR and PCR-free BIOSensors for the Detection of Resistance-associated SNPs in Pneumocystis JiroveciiUniversity Hospital, Brest
- RECRUITINGPHASE2NCT05835479Rezafungin for Treatment of Pneumocystis Pneumonia in HIV AdultsMundipharma Research Limited
- RECRUITINGNCT07269314Introduction of Polymerase Chain Reaction (PCR) in Microbiology and ParasitologyFondazione IRCCS Policlinico San Matteo di Pavia
- RECRUITINGNCT06691321Caspofungin for Pneumocystis Pneumonia in PLWHIV.Instituto Nacional de Enfermedades Respiratorias
- ENROLLING BY INVITATIONNANCT03856229Short-term Steroid Therapy in Patients With P. Jirovecii Pneumonia Due to HIV / AIDSCentro de Investigación en. Enfermedades Infecciosas, Mexico